# Stéphane Bancel

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/stphane-bancel
Canonical HTML page: https://getbiobrief.com/entity/stphane-bancel

## Timeline

- **2026-08-05**: FDA Approval of mRNA-1010 — The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+.

## Recent coverage (3 stories)

### Moderna's mRNA-1010 Approved with 27.4% Efficacy Lead in 65+ Population
2026-08-06 21:00:31 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza.
Full story: https://getbiobrief.com/story/moderna-mrna-1010-fda-approval-27-4-percent-efficacy

### Moderna’s mFLUSIVA mRNA Flu Vaccine Wins FDA Nod: 40,000-Patient Trial Suggests Superiority
2026-08-06 20:24:09 · Sentiment: Positive · Impact: 6/10 · Sources: 3

The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Full story: https://getbiobrief.com/story/moderna-mrna-flu-vaccine-approval-fda

### Moderna's mRNA Flu Vaccine Gets FDA Greenlight—Trial Enrolled 40,805 Subjects
2026-08-06 04:49:18 · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

The U.S. FDA approved Moderna's mFLUSIVA, an mRNA seasonal influenza vaccine, for adults 50 and older. Data from two randomized trials, including a 40,805-subject Phase 3, supported the approval, with the 65+ cohort receiving accelerated approval. This milestone validates the mRNA platform beyond COVID-19 and positions Moderna to compete in the $5 billion+ global flu vaccine market.
Full story: https://getbiobrief.com/story/moderna-mflusiva-fda-approval-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.